50 million seniors age 60 and over to get Zostavax to prevent shingles

  New recommendations will call for about 50 million seniors age 60 and over to get Zostavax to prevent shingles.

  This new vaccine reduces the RELATIVE risk of shingles by about 50% and the ABSOLUTE risk by 1.7%. It also reduces the relative risk of postherpetic neuralgia by 67%...since fewer people get shingles.

  There are no significant side effects for most people.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote